Posted by Michael Wonder on 15 Aug 2019
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumour
15 August 2019 - FDA also approves drug for second indication in a type of lung cancer.
The U.S. FDA today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments.
Rozlytrek was also approved today for the treatment of adults with non-small cell lung cancer whose tumours are ROS1-positive (mutation of the ROS1 gene) and has spread to other parts of the body (metastatic).
